Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
N/A
1(25.0%)
Phase 4
1(25.0%)
4Total
Phase 1(2)
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07254416Phase 4Not Yet Recruiting

A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients

Role: collaborator

NCT07131345Phase 1Not Yet Recruiting

Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma

Role: collaborator

NCT04965428Not ApplicableUnknown

Fear-focused Self-Compassion Therapy for Young Breast Cancer Patients' Fear of Cancer Recurrence

Role: collaborator

NCT04182698Phase 1Unknown

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

Role: collaborator

NCT03724604Unknown

NSE/Alb as a Prognostic Biomarker for Lung Cancer

Role: collaborator

All 5 trials loaded